New lung cancer test predicts survival

	Tweet

How the Molecular Assay Predicts Lung Cancer Survival

The molecular assay is based on technology developed originally at UCSF. The assay itself was developed by Pinpoint Genomics, a company based in Mountain View, California, and relies on a standard laboratory technique known as quantitative polymerase chain reaction (qPCR).

The analysis begins with a piece of the patient’s cancerous tissue embedded in paraffin wax—the standard way of preserving all tissue samples removed during surgery. Material known as RNA, which reveals the relative activity level of genes within tissues, is then extracted from the tumors. The activity levels of 14 specific genes are then determined and compared to levels in normal lung. Eleven of these genes are linked to lung cancer biology, and the other three are common genes that are used to standardize the measurement of the cancer genes.

Pinpoint Genomics developed an algorithm for calculating risk of death after examining tissue taken from 361 patients at UCSF Medical Center who all had surgery to treat a common type of lung cancer called non-squamous, non-small cell lung cancer. The algorithm correlated the levels of these 14 genes with the clinical outcomes of these patients, the theory being that a molecular profile associated with a low, intermediate, or high risk of death in one patient could be used to predict a low, intermediate, or high risk in another patient.

To test their algorithm, the UCSF team partnered with Kaiser Permanente’s Division of Research in Oakland, CA and blindly examined lung samples taken from 433 other patients in northern California with the earliest stage of the same type of cancer. They also used a similar blinded approach to test the algorithm using tissue samples from 1,006 lung cancer patients in China, where lung cancer is one of the leading causes of death. No other clinical trial examining molecular prognostic indicators has ever demonstrated the same result in two different populations with different genetic make-ups on two continents, the team said.

The scientists found that the algorithm very accurately differentiated patients with high, intermediate or low risks of death in these larger cohorts of patients, even for patients with stage II and stage III lung cancer.

###
More information: “International, Large-Scale Validation of a Practical Molecular Assay Prognostic of Survival in Resected Non-Squamous, Non-Small Cell Lung Cancer”.

###
Provided by University of California, San Francisco

RELATED STORIES:
Lung cancer risk increases with expression of specific genes   Survey finds significant racial differences in lung cancer beliefs   Anti-estrogen medication reduces risk of dying from lung cancer   Personalized treatment for early lung cancer   Lung cancer patients with diabetes show prolonged survival   Inhaler treatment for lung cancer   Lung cancer screening often yields false positives   Lung cancer culprit could offer target for therapy, UT Southwestern researchers report   Gene fusion in lung cancer afflicting never-smokers may be target for therapy   Hispanic lung cancer patients tend to live longer than blacks and whites   US doctors resume test of drug to fight lung cancer   Genome Study Charts Genetic Landscape of Lung Cancer   Women often opt out of lung cancer studies   Family risk for lung cancer stronger in blacks   Ovary removal may increase lung cancer risk   Last-minute radiation saves lung cancer patients   Estrogen-only therapy may not up lung cancer deaths   Blood test may find early lung cancer: study   Nutrients may be why some smokers avoid cancer   Early Diagnosis of Lung Cancer: Where Do We Stand?   Race Not Root of Disparity in Lung Cancer Between Whites and Blacks   Lung cancer pill on NHS in 2007

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]